Why was coronary artery bypass grafting (CABG) not performed earlier in this patient presenting with an acute plaque‑rupture coronary event?

Why CABG Was Delayed in Acute Plaque-Rupture Coronary Event

In a hemodynamically stable patient with acute coronary syndrome who has received dual antiplatelet therapy (particularly ticagrelor), delaying CABG for 2-3 days to allow platelet function recovery significantly reduces bleeding complications and transfusion requirements without increasing ischemic risk, making this the preferred strategy over emergency surgery. 1

Primary Reason: Active Platelet Inhibition

The most common reason for delaying CABG in acute coronary syndrome is ongoing platelet inhibition from P2Y12 inhibitors (ticagrelor or clopidogrel) given at presentation:

• Ticagrelor within 2 days of CABG: Significantly higher bleeding rates and platelet transfusion requirements 1
• Ticagrelor 2+ days before CABG: Bleeding rates similar to patients not on ticagrelor, though platelet transfusions still slightly elevated 1
• Optimal timing: Day 3 after ticagrelor loading allows adequate platelet function recovery 1

The TARGET-CABG study demonstrated that platelet function testing can guide timing, reducing wait time by 50% while maintaining safety when surgery is performed after platelet normalization 1.

Clinical Decision Algorithm

Proceed with Emergency CABG if:

1. Failed PCI with persistent ischemia of significant myocardium AND hemodynamic instability 2, 3, 2
2. Cardiogenic shock refractory to medical therapy 2, 3, 4
3. Mechanical complications: ventricular septal rupture, papillary muscle rupture, free wall rupture 2, 3, 2
4. Life-threatening ventricular arrhythmias with left main ≥50% or 3-vessel disease 2

Delay CABG (Preferred Strategy) if:

1. Patient is hemodynamically stable with resolved ECG changes 1
2. No ongoing ischemia at rest 2, 3
3. No total occlusion of culprit vessel 1
4. Recent P2Y12 inhibitor loading (within 48 hours) 1

Bridging Strategy During Waiting Period

For stable patients awaiting delayed CABG:

• Intravenous antiplatelet agents (tirofiban, eptifibatide) for continued ischemic protection 1
• Intravenous heparin for anticoagulation 1
• High-dose statins 1
• Mechanical support (IABP) if needed for symptom stabilization 1
• Aspirin continuation 1

Evidence Supporting Delayed Approach

Observational data consistently show that early CABG (<24 hours) carries higher risk than delayed CABG (>24 hours) in acute coronary syndromes 1, though this is partially confounded by higher baseline risk in emergency cases. However, risk-adjusted analyses demonstrate no significant mortality difference with early surgery when appropriately selected 1.

The 2024 Canadian guideline explicitly describes a case where CABG was performed on day 3 after ticagrelor loading in a stabilized patient, resulting in no postoperative bleeding and improved left ventricular function at 3 months 1.

When PCI Should Be Performed Instead

If complete occlusion with cardiogenic shock exists, immediate PCI should restore flow even if anatomy favors CABG, allowing rapid stabilization until definitive CABG can be performed safely 1. This represents a "bridge to CABG" strategy.

Critical Pitfalls to Avoid

1. Do NOT perform emergency CABG in hemodynamically stable patients with small areas of viable myocardium 2, 3, 2
2. Do NOT perform emergency CABG in no-reflow states (successful epicardial but failed microvascular reperfusion) 2, 3, 2
3. Do NOT delay revascularization in cardiogenic shock—proceed with PCI or CABG immediately 2, 4, 5
4. Do NOT routinely perform multivessel PCI in cardiogenic shock (culprit-only strategy preferred) 4

Emerging Options

Bentracimab (ticagrelor reversal agent) shows promise for immediate and sustained reversal in patients requiring emergency surgery, potentially eliminating the need for delay 1. However, this remains investigational and is not yet standard practice.

Mortality Context

Emergency CABG in STEMI is now rare (3.2-10.9% of cases) 3 due to widespread primary PCI availability. When performed in unselected ACS populations, early CABG demonstrates very low in-hospital mortality (1.1%) despite being performed in higher-risk patients 6, supporting its use when appropriately indicated. The SHOCK trial showed that CABG provides similar benefit to PCI in cardiogenic shock, with 37% of revascularized patients receiving CABG 1.